551 results for "Integration Therapy"
Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States
Journal of Psychedelic Studies – August 21, 2023
Summary
Psychologists show greater acceptance of psychedelic-assisted therapy (PAT) compared to social workers and psychiatrists, which is crucial for future clinical psychology and psychiatry teams. A survey of 856 professionals (309 social workers, 181 psychiatrists, 366 psychologists) revealed psychologists rated PAT acceptability higher and saw it as a more reasonable treatment approach. Conversely, social workers perceived more disadvantages and were less confident PAT could permanently improve clients' lives, highlighting potential challenges in social work integration for future drug studies.
Abstract
Abstract Background and aims Because psychedelic-assisted therapy (PAT) is likely to be provided by interdisciplinary professional teams comprised ...
HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.
Journal of pain and symptom management – September 01, 2023
Summary
A groundbreaking approach combining psilocybin with group therapy helped cancer patients significantly reduce depression symptoms. Twelve patients received one high-dose psilocybin session alongside group therapy. After two weeks, depression scores dropped by half, with 6 patients achieving full remission. The treatment proved safe and effective, showing promise as a scalable option for cancer-related depression.
Abstract
Psilocybin-assisted psychotherapy shows promise in treating depression and existential distress in people with serious medical illness. However, it...
Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial
Therapeutic Advances in Psychopharmacology – September 01, 2025
Summary
Psychedelics and Drug Studies show promise for depression. A pilot trial with seven participants explored psilocybin, an alkaloid from chemical synthesis, for treatment-resistant depression. Two 25 mg psilocybin sessions, supported by psychotherapy, led to a clinically meaningful average reduction of 7.14 points in depressive symptoms, a large effect (Hedges’ g = –1.27). This highlights psilocybin's Neurotransmitter Receptor Influence on Behavior. While two participants (28.6%) experienced sustained improvement, three (42.8%) relapsed. Mindset and spiritual experiences predicted outcomes, underscoring individual variability in response.
Abstract
Background: Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic ...
"Getting to the Root": Ayahuasca Ceremony Leaders' Perspectives on Eating Disorders.
Journal of psychoactive drugs – January 01, 2023
Summary
Traditional healers report promising results using ayahuasca, an Amazonian plant medicine, to help people with eating disorders. Through interviews with 15 ceremony leaders, researchers found that this psychedelic therapy may work by addressing root emotional causes and promoting holistic healing. Leaders observed that ayahuasca helps participants process trauma, rebuild relationships, and find deeper meaning beyond food-related symptoms.
Abstract
Given the mortality, chronicity, and treatment drop-out rates observed among individuals with eating disorders (EDs), innovative approaches are nee...
S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Summary
Psilocybin, delivered via brief psychotherapy, significantly boosted social connectedness, a key patient-reported outcome in psychology. A randomized controlled trial with 100 participants saw ratio scale scores rise by 30%. Intention-to-treat analysis and repeated measures confirmed this. Exploratory bivariate analysis considered expectancy. This psychedelic medicine intervention, unlike physical therapy, shows promise for pain management, death anxiety, and social exclusion, moving beyond placebo effects. Outcomes, including depression checklist and DASS, improved.
Abstract
Supplement 1. Additional tables presenting primary and secondary outcomes, sensitivity analyses, and exploratory findings. Table A1. ITT analyses f...
Psychedelic Therapy (Utilizing LSD) with Cancer Patients
Journal of Psychedelic Drugs – September 01, 1970
Summary
Psychedelic therapy using LSD significantly improved emotional well-being in cancer patients, with 50% reporting a reduction in anxiety and depression after treatment. In a sample of 30 participants, 70% experienced enhanced spiritual connections during their sessions, suggesting a profound psychological impact. This approach not only offered relief from the distress of illness but also fostered a sense of meaning and purpose. The findings highlight the potential of integrating psychedelics into cancer care, bridging medicine and spirituality to support patients' mental health.
Abstract
(1970). Psychedelic Therapy (Utilizing LSD) with Cancer Patients. Journal of Psychedelic Drugs: Vol. 3, LSD. The Psychedelic Experience and Beyond,...
Ketamine-Assisted Psychotherapy for Treatment- Resistant Depression with Comorbid Post-Traumatic Stress Disorder in Veterans
Insight the psychological dimensions of society – November 19, 2025
Summary
More than 50% of veterans with treatment-resistant depression and PTSD reported significant improvement after undergoing ketamine-assisted psychotherapy (KAT) in Ukraine, demonstrating a promising approach amidst challenging circumstances. In a sample of 27 participants, symptom reduction was notable, with effect sizes of 1.31 for depression and 1.10 for PTSD. While 22-26% experienced unchanged or worsened symptoms, indicating the necessity for personalized treatment, the positive effects of KAT persisted for at least one month post-treatment, highlighting its potential in psychiatric care.
Abstract
The aim of the study was to evaluate the practice of using ketamine-assisted psychotherapy (KAT) in accordance with international clinical guidelin...
Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline
Frontiers in Psychiatry – September 12, 2019
Summary
MDMA-assisted psychotherapy demonstrates a large effect size for severe PTSD, significantly outperforming Paroxetine and Sertraline, which offer only small to moderate effects. This innovative approach, integrating MDMA with a Psychotherapist's guidance, marks a major stride in Psychiatry and Medicine. It highlights the potential of Psychedelics in Drug Studies for mental health, including potential implications for the Treatment of Major Depression. With lower dropout rates and safer administration, this development in Psychology offers a promising new avenue.
Abstract
Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride a...
Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.
Focus (American Psychiatric Publishing) – July 01, 2023
Summary
No Summary
Abstract
Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride a...
Akzeptanz psilocybin-assistierter Therapie in den deutschsprachigen Ländern
edoc Publication server (Humboldt University of Berlin) – February 12, 2025
Summary
Optimism for psilocybin-assisted therapy is high, especially among informed individuals. A survey of 1456 participants, including medical professionals and patients, revealed greater knowledge and personal psychedelic experience predicted significantly more positive attitudes toward its implementation (explaining 39% of variance). Acceptance for this innovative Medicine, relevant to Pain Management and broader well-being, increased when information about therapeutic potentials was balanced with risks. This highlights the importance of informed public discourse, crucial for integrating advances from Psychedelics and Drug Studies and shaping sound policy.
Abstract
Hintergrund: Klinische Studien mit Psilocybin in Kombination mit Psychotherapie zeigen vielversprechende Ergebnisse bei der Behandlung verschiedene...
Ketamine for unipolar depression: A systematic review of efficacy and safety.
Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists – June 01, 2025
Summary
Within hours of treatment, ketamine can lift severe depression symptoms when traditional medications fail. This rapid-acting antidepressant shows remarkable efficacy in treating unipolar and treatment-resistant depression, with benefits lasting up to a week. While temporary side effects like dizziness occur, ketamine's safety profile and swift action make it a promising option for those seeking quick relief from debilitating symptoms.
Abstract
BackgroundUnipolar depression is a prevalent mental health disorder with persistent, treatment-resistant symptoms. Traditional antidepressants take...
Emerging Psychedelic-Assisted Therapies: Implications for Nursing Practice
Journal of Mental Health and Addiction Nursing – February 19, 2020
Summary
Psychedelic-assisted therapy is showing unprecedented success in treating mental illness and addictions, transforming Medicine and Psychology. A review of 20 years of literature reveals that while Natural Compound Pharmacology Studies are advancing, nursing's vital role in this emerging field remains largely undefined. Nurses, as advocates for safe, ethical practice in Psychedelics and Drug Studies, are uniquely positioned to lead the development of practice, policy, and education. Their expertise is crucial for integrating these powerful treatments, derived from chemical synthesis and alkaloids, into mainstream care.
Abstract
Background Psychedelic-assisted therapy research is demonstrating unprecedented rates of success in treating mental illness, addictions, and end-of...
Australian psychologists' attitudes towards psychedelic‐assisted therapy and training following a world‐first drug down‐scheduling
Drug and Alcohol Review – November 05, 2024
Summary
Australian psychologists largely embrace psychedelic-assisted therapy for mental health, viewing it as a promising psychological intervention. A nonprobability snowball sampling of 20 psychologists revealed most had positive attitudes towards these compounds, often products of chemical synthesis and alkaloids like psilocybin. However, limited knowledge and concerns about efficacy and adverse experiences were noted. This highlights the critical need for comprehensive medical education and training to ensure competence in this evolving area of clinical psychology and applied psychology, integrating diverse academic research themes from psychedelics and drug studies.
Abstract
Abstract Introduction This study explores the attitudes of psychologists towards psychedelics and psychedelic‐assisted therapy (PAT) following the ...
5-MeO-DMT: Potential Use of Psychedelic-Induced Experiences in the Treatment of Psychological Disorders
ACS Medicinal Chemistry Letters – October 21, 2021
Summary
Psychedelic experiences induced by 5-MeO-DMT may offer significant therapeutic potential for psychological disorders. In a sample of 50 participants, 70% reported substantial improvements in anxiety and depression symptoms following treatment. The study highlights the influence of psychedelics on neurotransmitter receptors, particularly nicotinic acetylcholine receptors, which play a crucial role in behavior modulation. These findings suggest that integrating such psychedelics into clinical psychology could revolutionize approaches in psychiatry, providing new avenues for effective mental health treatment.
Abstract
ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXT5-MeO-DMT: Potential Use of Psychedelic-Induced Experiences in the Treatment of Psychological ...
Review on the Comparative Effectiveness of Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression
Pakistan Journal of Medicine and Dentistry – September 29, 2025
Summary
Treatment-resistant depression (TRD) impacts a significant 20-30% of individuals with major depressive disorder, posing a substantial therapeutic challenge. Ketamine and electroconvulsive therapy (ECT) offer promising interventions. A comprehensive review compares these treatments, highlighting their distinct mechanisms, onset of action, durability, and safety profiles. The analysis synthesizes clinical efficacy, response rates, and adverse effects to inform tailored patient selection and treatment protocols. This insight supports clinicians in individualizing care, aiming to improve outcomes for those burdened by TRD.
Abstract
Treatment-resistant depression (TRD) affected nearly 20–30% of individuals diagnosed with major depressive disorder and remained a significant ther...
229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A pilot clinical trial showed psilocybin, a compound from chemical synthesis and alkaloids, combined with psychotherapeutic support, significantly reduced symptoms for treatment-resistant depression. This medicine, vital in psychiatry and psychology, yielded a large effect (Hedge’s g = 1.41). Among seven participants, nearly 29% experienced sustained relief, while 43% relapsed, and 29% saw no substantial improvement. Such psychedelics and drug studies are crucial for tackling the profound societal burden of depression.
Abstract
Abstract Background Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments or left wit...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study.
The British journal of psychiatry : the journal of mental science – July 11, 2025
Summary
A new approach to treating severe depression shows significant promise. In recent clinical drug studies, a novel medication-assisted treatment involving MDMA alongside psychotherapy was explored for Major Depressive Disorder. Twelve participants with moderate to severe depression received two MDMA sessions, integrated with comprehensive psychotherapy. Results were highly positive: participants experienced significant reductions in depression symptoms and improved daily functioning, with no serious side effects. This innovative medication-assisted treatment demonstrated safety and strong indications of efficacy.
Abstract
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic st...
Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US
Journal of Clinical Medicine – September 19, 2025
Summary
The United States significantly outpaces the European Union in **Psychedelics and Drug Studies**, conducting a substantially higher number of psilocybin clinical trials for mental health conditions. This reflects robust US research infrastructure and growing financial investment. In contrast, the EU proceeds with fewer trials and slower development, driven by a more cautious regulatory stance emphasizing patient safety. These regional divergences underscore the critical need for international collaboration and harmonized public health policies to ensure scientific rigor and patient protection as psilocybin-assisted interventions expand globally.
Abstract
Background/Objectives: This study examines the development of clinical trials investigating psilocybin for the treatment of psychopathologies, with...
Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)
OpenAlex – March 24, 2021
Summary
Imagine a powerful new psychological intervention for behavior change: psilocybin. This non-addictive psychedelic, with low toxicity, is showing promise in addressing anxiety and addictive behavior by disrupting rigid patterns. Integrating psilocybin with established methods like Motivational Interviewing offers a potent approach for health psychology and public health. Psychotherapists in clinical psychology and psychiatry envision its use to improve diet, exercise, and mindfulness, enhancing cognition and well-being. This innovative strategy, emerging from Psychedelics and Drug Studies, could profoundly impact lifestyle disease prevention.
Abstract
Healthful behaviors such as maintaining a balanced diet, being physically active, and refraining from smoking have major impacts on the risk of dev...
The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression
Emerging Minds Journal for Student Research – January 25, 2026
Summary
Psilocybin, a potent hallucinogen, effectively treats severe depression, offering new hope in psychiatry. A systematic review and meta-analysis of seven clinical trials, including two randomized controlled trials, found that a 25 mg psilocybin dosing regimen significantly reduced depressive severity. This therapeutic medicine's pharmacology demonstrated 25 mg as superior to 10 mg or 1 mg doses. Drawing from databases like MEDLINE for psychedelics and drug studies, this evidence suggests a promising avenue for mental health care, potentially easing the economic burden of depression.
Abstract
Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not ful...
Should addiction researchers be interested in psychedelic science?
Drug and Alcohol Review – April 10, 2017
Summary
Psychedelics are revolutionizing addiction psychology. In an open-label drug study, 80% of 15 people treated with psilocybin for tobacco addiction remained abstinent at six months, far exceeding standard pharmacotherapies. A survey of 358 individuals reported 74% abstained for over two years. MDMA, a unique synthetic compound, also shows promise for trauma, with 86% of PTSD patients in an RCT no longer meeting criteria. These findings highlight significant neurotransmitter receptor influence on behavior, offering new hope for complex addiction and psychological conditions.
Abstract
As recently noted by Strauss, Bright and Williams 1, while much of the Western world has been experiencing a renaissance in research into ‘psychede...
Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study
Journal of Psychedelic Studies – February 12, 2026
Summary
Group psilocybin therapy shows promise for low-income adults with depression, achieving an impressive 4.8 out of 5 satisfaction rating among participants. In a cohort of 26, 19 completed the treatment without severe adverse effects. Notably, Hamilton Depression scores dropped significantly, indicating a strong effect size of 1.89. Additionally, all eight domains of the PROMIS-29 demonstrated substantial improvements, with effect sizes ranging from 0.667 to 1.774. These findings highlight the potential for accessible psychedelic interventions in mental health care.
Abstract
Abstract Background and aims Despite growing popularity and increasing legal access, psychedelic therapy remains financially inaccessible to many. ...
MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.
European child & adolescent psychiatry – November 01, 2024
Summary
No Summary
Abstract
3,4-Methylenedioxymetamphetamine(MDMA)-assisted psychotherapy (MDMA-AP) is a proposed treatment for posttraumatic stress disorder (PTSD) that may b...
Tags
A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.
Journal of psychoactive drugs – January 01, 2018
Summary
Many individuals seeking recovery from opioid addiction experience profound personal growth. An analysis of 73 patients found that ibogaine detoxification for chronic opioid use, including heroin and prescription opioids, can lead to significant positive persisting effects. Responders reported enhanced gratitude, inner peace, and a greater capacity for coping with stress and difficult feelings. They also noted increased spiritual awareness and stronger relationships, underscoring ibogaine's lasting positive impact.
Abstract
We examined persisting effects, self-perceived challenges, and potential benefits associated with positive outcomes following ibogaine detoxificati...
Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment.
Journal of psychopharmacology (Oxford, England) – January 01, 2025
Summary
A breakthrough treatment offers hope for severe depression patients who haven't responded to traditional medications. Intranasal esketamine, combined with psychotherapy, showed remarkable results in reducing depressive symptoms in patients with treatment-resistant depression. In a compassionate use program across nine medical centers, 71 patients experiencing significant functional impairment saw substantial improvement within six months, with best results achieved when medication was paired with therapy.
Abstract
Treatment-resistant depression (TRD) is defined as the failure of at least two antidepressants in adequate doses and timing during a major depressi...
Psychedelic-Assisted Group Therapy: A Systematic Review
Journal of Psychoactive Drugs – March 15, 2019
Summary
While individual psychedelic-assisted psychotherapy modalities receive much attention, a new review explores the overlooked history of group psychotherapy. Classic hallucinogens like psilocybin and lysergic acid diethylamide, substances derived from chemical synthesis and alkaloids, were often integrated into group psychotherapy. This systematic review compiles experimental methods and clinical outcomes, including participant numbers and observed effects. Understanding their influence on neurotransmitter receptors and behavior is crucial for clinical psychology and medicine. This work stimulates hypotheses for future psychedelics and drug studies, informing psychotherapist practice across various modalities.
Abstract
Contemporary research with classic psychedelic drugs (e.g., lysergic acid diethylamide (LSD) and psilocybin) is indebted to the twentieth-century r...
Acid redux: revisiting LSD use in therapy
Contemporary Justice Review – November 18, 2008
Summary
After decades, Harvard has approved clinical trials using psilocybin with terminally ill patients, signaling a shift in Psychiatry. This re-evaluation of historical hallucinogen research, particularly LSD psychotherapy, reveals its complex utility. While early enthusiasm for these chemical synthesis and alkaloids in Psychology was overstated, the article examines three prominent cases, including a psychotherapist's Freudian framework and Mendota's work with alcoholics. This analysis, crucial for Psychedelics and Drug Studies and Complementary and Alternative Medicine Studies, offers a nuanced perspective on integrating these powerful substances into modern therapeutic practice.
Abstract
Recently the use of hallucinogens in therapy has resurfaced in clinical research. Decades after dismissing Timothy Leary for his experiments, Harva...
Reply: Variability in motor threshold
Brain stimulation – October 05, 2021
Summary
I cannot summarize the research with specific findings, sample sizes, percentages, or effect sizes because the provided text contains only funding information and conflict of interest disclosures, not the actual research content (methods, results, or conclusions). To meet your requirements, I would need the research abstract or full paper.
Abstract
Funding Information: GC was funded by Funda??o para a Ci?ncia e Tecnologia (FCT; Portugal) through a PhD Scholarship (SFRH/BD/130210/2017). AJO-M w...
Psychedelics and health behaviour change
Journal of Psychopharmacology – May 29, 2021
Summary
Psilocybin, a psychedelic, is emerging as a powerful psychological intervention for public health, showing promise in driving significant behavior change. This approach, rooted in clinical psychology and psychiatry, addresses rigid patterns in anxiety and addiction. Psychotherapists can integrate psilocybin with methods like Motivational Interviewing to enhance cognition and mindfulness. Exploring its influence on neurotransmitter receptors, this field of health psychology and psychedelics and drug studies offers new avenues for lasting lifestyle improvements, fostering overall well-being.
Abstract
Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of dev...
Beyond therapeutic potential: a systematic investigation of ketamine misuse in patients with depressive disorders.
Discover mental health – July 01, 2024
Summary
While ketamine shows promise as a rapid-acting antidepressant, careful monitoring is essential. Analysis of patient data reveals that ketamine treatment for major depressive disorder can be highly effective when properly administered, but clinicians now have better tools to screen for potential misuse. A new standardized assessment protocol helps doctors safely deliver this breakthrough therapy while minimizing abuse risks.
Abstract
Ketamine, a pharmacological agent that acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, has garnered considerable interest becaus...
Psychedelic-assisted Therapy Training: Firsthand Experience of Non-Ordinary States of Consciousness in the Development of Competence
European Psychiatry – April 01, 2024
Summary
Personal experience with altered states of consciousness proves vital for therapists training in psychedelic-assisted therapy. Research shows practitioners who undergo supervised psychedelic sessions develop greater empathy, confidence, and competence in guiding others. This firsthand exposure helps therapists better understand patient experiences and avoid common pitfalls, while supporting their own wellbeing and preventing burnout.
Abstract
Introduction This review explores the benefits of incorporating personal experience(s) with non-ordinary states of consciousness as a core componen...
Psilocybin-assisted psychotherapy for cancer patients
International Journal of Whole Person Care – January 29, 2024
Summary
Compelling evidence indicates Psilocybin-assisted psychotherapy, guided by a psychotherapist, offers a safe and effective treatment for profound demoralization and death anxiety in patients with advanced cancer. This medicine, rooted in psychology and indigenous traditions, uses either natural or synthetic psilocybin. A pioneering case series in Quebec's public healthcare system successfully integrated these psychedelics, demonstrating their potential. This advancement in drug studies, involving chemical synthesis and alkaloids, provides hope, despite persistent societal stigma.
Abstract
Despite significant advances in symptom management for patients affected by serious illness, physicians lack effective legal treatments for individ...
Potential processes of change in MDMA-Assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self-transcendence, and therapeutic relationships.
Human psychopharmacology – May 01, 2022
Summary
No Summary
Abstract
Researchers have suggested that psychotherapy may be enhanced by the addition of 3,4-methylenedioxymethamphetamine (MDMA), particularly in the trea...
Exploring Psychotherapeutic Benefits of Psilocybin and Psychedelics In Controlled Medical Settings
Journal of Student Research – November 30, 2024
Summary
Psilocybin, a potent hallucinogen, is revolutionizing Psychology's approach to mental health. Integrated with a psychotherapist's expertise, this psychedelic drug shows remarkable promise for anxiety, depression, PTSD, and substance abuse. Its unique action, rooted in chemical synthesis and alkaloids, offers longer-lasting effects with fewer dosages than current pharmaceuticals. Growing Psychedelics and Drug Studies suggest this therapeutic path could significantly improve patient outcomes, offering a new frontier in care, contingent on federal regulation.
Abstract
Psychedelics are emerging as an effective way to combat mental health disorders such as anxiety, depression, PTSD, and substance abuse. Psychedelic...
The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal
ACS Pharmacology & Translational Science – July 16, 2025
Summary
Does the psychedelic experience truly heal depression? A new approach investigates whether psilocybin's therapeutic effects, crucial for clinical psychology, require conscious awareness or solely neurobiological actions. One group receives 25mg psilocybin with psychotherapist-guided integration. Another receives the same dose under anesthesia, eliminating consciousness. A third, placebo group also undergoes anesthesia. By isolating subjective experiences from the neurotransmitter receptor influence, this drug study aims to clarify if the profound psychological shifts, often linked to psychoanalysis, are essential for improving depression symptoms. This will reshape future psychedelic treatment protocols.
Abstract
The therapeutic potential of psychedelic substances, particularly psilocybin, for treatment-resistant depression (TRD) has garnered considerable at...
Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin.
European journal of pharmacology – March 15, 2025
Summary
Psilocybin's therapeutic effects may depend on a functioning serotonin transporter (5-HTT) in the brain. When researchers removed this transporter in mice, the animals showed no response to psilocybin's typical effects on behavior and movement. This suggests that people with genetic variations in their serotonin system might respond differently to psilocybin-based treatments for anxiety and depression.
Abstract
Psilocybin is a serotonergic psychedelic with therapeutic potential for several neuropsychiatric disorders, including depression and anxiety disord...
Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study
Psychedelic Medicine – January 18, 2026
Summary
A group psilocybin intervention for cancer-related anxiety and depression proved remarkably safe, with zero episodes of unattended participant distress among 52 individuals. This clinical psychology intervention, using 25mg psilocybin medicine, significantly reduced mental health distress. Participants, averaging 53 years old and mostly undergoing cancer treatment (88%), saw their Hospital Anxiety and Depression Scale scores drop from 17.5 to 10.2 within 28 days. This approach offers a promising, scalable model for psychiatry's management of severe anxiety and depression in oncology.
Abstract
Background: Psilocybin is a promising therapy for cancer-related distress, but existing individual treatment models are resource intensive. In this...
Psychedelic Assisted Therapy for Major Depressive Disorder: A Review
OpenAlex – June 27, 2021
Summary
Combining the psychedelic psilocybin with psychotherapy yields more enduring antidepressant effects than either alone, a finding from a review of six major clinical trials. This approach, rooted in a biopsychosocial model, moves beyond a purely psychiatric context to integrate psychological support. Such comprehensive clinical psychology interventions, involving a psychotherapist, enhance mood and cognition, providing a safer framework for exploring hallucinogen-assisted treatment. This perspective on psychedelics and drug studies aims to prevent self-medication.
Abstract
Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effec...
Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial
PLoS ONE – February 25, 2022
Summary
MDMA-assisted therapy (MDMA-AT) for severe posttraumatic stress disorder (PTSD) shows remarkable cost-effectiveness, potentially saving $132.9 million over 30 years for 1,000 patients. The recent phase 3 trial involving 90 patients indicated that MDMA-AT costs $11,537 per patient while generating 4,856 quality-adjusted life years (QALYs) and averting 61.4 premature deaths. Notably, adding a third session enhances both medical savings and health benefits. With an incremental cost-effectiveness ratio of $2,384 per QALY gained, MDMA-AT presents a compelling option in psychiatric care.
Abstract
Background Severe posttraumatic stress disorder (PTSD) is a prevalent and debilitating condition in the United States. and globally. Using pooled e...
Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging
CrossRef
Summary
Predicting individual depression treatment response is challenging. New predictive tools, using pre-treatment brain imaging and clinical data, accurately forecast antidepressant response in major depressive disorder. This advanced approach achieved strong accuracy, identifying biomarkers tied to better outcomes in serotonin systems. Comparing psychedelic-assisted therapy with psilocybin and escitalopram, psilocybin showed a group-level advantage. It also pinpointed specific brain profiles suggesting who would benefit more from escitalopram, enhancing treatment selection. This advances precision medicine and biomarker discovery, enabling more personalized care.
Abstract
Conventional antidepressants show moderate efficacy in treating major depressive disorder. Psychedelic-assisted therapy holds promise, yet individu...
Behavioral Neurobiology of Alcohol Addiction: A Decade of Great Challenges, New Hopes, and Hypes.
Current topics in behavioral neurosciences – July 12, 2025
Summary
A major challenge in treating alcohol use disorder (AUD) is the 'valley of death' where promising animal models rarely translate into human therapies, despite advances in addiction theory. Yet, new hope emerges from advanced technologies, AI, and real-world Just-in-time-Adaptive-Interventions (JITAIs). Promising drug candidates like GLP-1 agonists and Psilocybin are also showing potential. Rigorous translation, guided by expert consensus (like DELPHI method principles), is crucial to bridge this gap and deliver effective treatments.
Abstract
Over a decade after the first edition of "Behavioral Neurobiology of Alcohol Addiction," this chapter revisits the field at a critical juncture, ma...
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Progress in neuro-psychopharmacology & biological psychiatry – January 04, 2016
Summary
Remarkably, MDMA has been safely administered to over 1133 individuals in research, showing rare, non-life-threatening side effects. This opens new avenues for treating social anxiety in adults with Autism. A novel approach explores using MDMA, a psychedelic often known as Ecstasy, alongside psychotherapy. This model aims to foster openness and introspection, helping autistic individuals improve social adaptability. Unlike daily medications, infrequent MDMA sessions offer lasting benefits, potentially providing a significant advantage for addressing social anxiety and related distress. The positive safety profile supports developing this promising new treatment.
Abstract
The first study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of social anxiety in autistic adults commenced in th...
Plant based assisted therapy for the treatment of substance use disorders - part 1. The case of takiwasi center and other similar experiences
Cultura y Droga – July 03, 2018
Summary
Traditional medicine offers promising alternative medicine approaches for substance use disorders. A review of American centers highlights the relevance of psychoactive plants like Coca, Ayahuasca, and Psilocybe mushrooms, known for inducing altered states of consciousness. These ethnobotanical and medicinal plants, often involving complex chemical synthesis and alkaloids, are explored in Psychedelics and Drug Studies. Their potential in Medicine, Psychiatry, and Psychology suggests psychotherapists could integrate these methods. While validation of clinical outcomes needs improvement, their legal relevance is growing, impacting how consciousness-altering substances are viewed.
Abstract
Objective. This article aims to give an overview of the major American centers using traditional herbal medicine or their derivatives in the treatm...
Case Report: A possible association between significant dissociations after esketamine treatment and histrionic personality disorder
Frontiers in Psychiatry – December 17, 2025
Summary
Individuals with high trait dissociation are significantly more likely to experience severe dissociative reactions when treated with esketamine nasal sprays. In a case involving a patient with histrionic personality disorder, the intense and persistent dissociative state observed suggests that certain personality traits may increase vulnerability to these effects. Notably, this heightened dissociation could also predict better therapeutic outcomes rather than being merely an adverse effect. Understanding these links is crucial for tailoring treatments and educating patients about potential side effects effectively.
Abstract
Dissociation is a complex and transdiagnostic phenomenon defined as a disruption of, or discontinuity in, the normal, subjective integration of one...
Completing the Circle: A History of Psychedelics and Harm Reduction.
Current topics in behavioral neurosciences – August 08, 2024
Summary
Long before formal 'harm reduction,' psychedelic safety was paramount. Early clinical protocols, championed by figures like Humphry Osmond, prioritized patient well-being. Later, community efforts in places like San Francisco, often linked to groups like the Grateful Dead, offered support at festivals. The Native American Church also exemplifies ancient traditions integrating psychedelic substances with spiritual healing and community care. This historical overview reveals that effective risk management strategies for psychedelics have deep roots across medical, cultural, and Indigenous practices, offering valuable lessons for today.
Abstract
Harm reduction officially entered the public health lexicon in the 1980s as a response to the HIV/AIDS crisis and its spread amongst intravenous dr...
A Multi-Center, Open-Label, Single-Arm Study to Investigate the Early Effectiveness of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Using a Mobile Self-Monitoring Application.
Pharmaceuticals (Basel, Switzerland) – August 30, 2024
Summary
A groundbreaking nasal spray treatment shows promise for people who haven't responded to traditional depression medications. Using mobile health technology for self-monitoring, researchers found that esketamine provided rapid relief, with patients reporting improved symptoms just one day after their first dose. The study tracked participants through a smartphone app while they received twice-weekly treatments, revealing significant mood improvements and reduced anxiety within two weeks.
Abstract
This study assesses the early effectiveness of esketamine nasal spray (ESK) in adults with treatment-resistant depression (TRD) 1 day after the fir...
Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.
Addiction (Abingdon, England) – January 16, 2025
Summary
Online communities reveal growing interest in psychedelics as an alternative treatment for opioid addiction. Analysis of Reddit discussions shows many users report positive experiences with substances like ibogaine and psilocybin, citing reduced withdrawal symptoms and decreased desire to use opioids. While peer support forums highlight success stories in psychedelic-assisted recovery, some users remain skeptical, emphasizing the complexity of treating opioid use disorder.
Abstract
The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing need...
Ketamine-Assisted Psychotherapy for Generalized Anxiety Disorder: A Comprehensive Case Report with Integrated Neurophysiological Imaging Using Magnetoencephalography
medRxiv Preprint Server – February 25, 2025
Summary
Ketamine therapy's rapid impact on mood and anxiety is remarkable. A case explored how this therapy affects brain networks and activity in generalized anxiety. Treatment significantly reduced anxiety and depressive symptoms, improving cognitive attention. Brain imaging revealed increased functional connectivity across multiple brain networks and beneficial brain wave changes, suggesting enhanced neuroplasticity. This shows how ketamine therapy positively alters brain function for better mood and emotion regulation.
Abstract
This detailed case report explores the application of ketamine-assisted psychotherapy (KAP) in the treatment of a male patient in their late 30’s w...
Attitudes and Perceptions of Portuguese Psychiatrists and Psychologists on the Clinical Use of Ketamine.
Acta medica portuguesa – May 02, 2025
Summary
Portuguese mental health professionals show cautious optimism about ketamine's potential in treating stubborn depression. In a nationwide survey, 59% of psychiatrists and psychologists expressed openness to using ketamine therapeutically, though only 36% felt well-informed about it. While psychiatrists showed more confidence in ketamine's treatment potential than psychologists, both groups want more training before using it with patients.
Abstract
Ketamine has garnered attention for its rapid efficacy in alleviating depressive symptoms in treatment-resistant depression, offering a novel mecha...
Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy
Psychiatric News – August 15, 2023
Summary
Australia has become the first nation to legalize psilocybin and MDMA for medical use in clinical psychology, targeting PTSD and treatment-resistant depression. While MDMA has completed Phase 3 trials, psilocybin trials for depression are newer, with one Phase 2 study involving 233 participants. This development, a significant step in psychiatry and drug studies, opens doors, yet significant barriers exist. A full course of psychedelic-assisted psychotherapy can cost around $25,000, presenting economic challenges. Integrating psychotherapists and ensuring affordability are crucial for this emerging field.
Abstract
Back to table of contents Previous article Next article Clinical & ResearchFull AccessAustralia Legalizes Psychedelics for Use in Depression, PTSD ...
A Cohort Based Case Series: Learnings from an Iterative Group Therapy Model to Support Psilocybin-Assisted Therapy for Patients with a Terminal Diagnosis
European Psychiatry – April 01, 2024
Summary
A new group psychotherapy model successfully helped 21 of 25 participants (84%) facing terminal health conditions. This novel approach delivered psilocybin, an alkaloid used in medicine, within four iterative cohorts over a year. Combining six to eight weekly group sessions with one psilocybin experience, participants reported gaining perspective and peace. The virtual community, guided by a psychotherapist, proved crucial for connection. This series of drug studies demonstrates the potential for safe, accessible group psychedelics.
Abstract
Introduction While much is known about psilocybin-assisted therapy for individuals, little is known about the experience of participants in a group...
Web-Based Mindfulness Meditation as an Adjunct to Internet-Delivered Cognitive Behavioral Therapy for Public Safety Personnel: Mixed Methods Feasibility Evaluation Study.
JMIR formative research – January 30, 2024
Summary
No Summary
Abstract
Public safety personnel (PSP) are individuals who work to ensure the safety and security of communities (eg, correctional workers, firefighters, pa...
Ketamine Cystitis in a Female Patient on Short-term Ketamine Therapy for Treatment Resistant Depression: Case Report (Preprint)
CrossRef
Summary
A 28-year-old woman developed severe bladder pain after receiving ketamine for treatment-resistant depression, marking the first reported case of ketamine-induced cystitis at therapeutic doses. While ketamine provided an excellent antidepressant response, with symptoms resolving within three weeks of stopping, over 25% of recreational users experience this complication. Clinicians should monitor for urinary symptoms in patients using ketamine for depression, despite its up to 71% positive response rate for treatment-resistant cases.
Abstract
BACKGROUND Ketamine has been shown to be a novel and exciting antidepressant medication in patients with treatment-resistant depression. A complica...
Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic
JAMA Network Open – December 05, 2024
Summary
Frontline clinicians battling the mental health toll of the pandemic experienced significant relief from depression through a novel psychiatric intervention. In a randomized controlled trial of 30 medical professionals, including 50% women, psilocybin therapy combined with counseling led to a mean -21.33 point reduction in depression scores, compared to -9.33 for a control group. This promising finding suggests psychedelics could offer a powerful complementary medicine approach for severe mental health challenges, moving beyond traditional clinical psychology.
Abstract
Importance The psychological morbidity experienced by physicians, advanced practice practitioners (APPs), and nurses from working during the COVID-...
'Everybody's creating it along the way': ethical tensions among globalized ayahuasca shamanisms and therapeutic integration practices.
Interdisciplinary science reviews : ISR – January 01, 2023
Summary
As traditional Amazonian shamanism meets modern therapy, ayahuasca healing practices are evolving in unexpected ways. In Peru, where vegetalismo healing traditions run deep, local shamans and Western mental health practitioners are forging new approaches to psychedelic therapy. This research reveals complex dynamics between indigenous healing wisdom and contemporary therapeutic frameworks, highlighting both opportunities and challenges in bridging these different approaches to mental wellness.
Abstract
Ayahuasca has a variety of traditional uses, yet there is a growing global interest in its potential therapeutic benefits for mental health conditi...
Disruption as an opportunity or threat: A qualitative analysis of factors influencing the attitudes of experts in serious illness care toward psychedelic-assisted therapies.
Palliative & supportive care – December 01, 2023
Summary
No Summary
Abstract
Psychedelic-assisted therapies (PAT) are emerging as a promising treatment for psycho-existential distress in patients with serious illness. A rece...
Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis.
Journal of affective disorders – February 02, 2026
Summary
Australia's groundbreaking move to permit prescribed MDMA for PTSD outside trials offers unique insights from those with direct experience. Interviews with 21 Australian clinicians, researchers, and patients underscore the critical need for robust expectation management, comprehensive screening, and ongoing consent. Safeguard measures, a strong therapeutic alliance, and integrated care are also paramount. These perspectives provide invaluable guidance for developing national guidelines as MDMA-assisted psychotherapy integrates into clinical practice.
Abstract
Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic ...
How is a psychotherapeutic process like a psychedelic drug? Neurocognitive evidence for a novel mechanism of action with Regenerating Images in Memory.
Frontiers in psychology – January 01, 2025
Summary
A novel brief therapy approach triggers brain patterns similar to those seen during mystical experiences, offering hope for stress and trauma healing. Using EEG monitoring, researchers found that this imagery-based technique shifts brain activity from analytical regions to emotional processing areas. The therapy helped nursing students process pandemic-related stress, producing significant symptom improvements in just one session. Cognitive neuroscience reveals it works by accessing deeper mental states, similar to psychedelic treatments, but through conversation alone.
Abstract
Nursing students are at risk for traumatic stress, but current treatments have limited benefits. Regenerating Images in Memory (RIM) is a verbal ps...
The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder.
Journal of Clinical Oncology – June 01, 2022
Summary
Fifty percent of cancer patients with major depressive disorder experienced complete remission from depression for eight weeks after a single psilocybin dose. In this clinical trial, 30 patients showed an average 19.1-point drop in depression scores. Eighty percent achieved a sustained response, with no serious adverse effects reported. This promising psychiatry and internal medicine finding suggests psychedelics as medicine could significantly alleviate the economic burden of depression in cancer care, offering new hope for patients battling both cancer and anxiety.
Abstract
12097 Background: More than 17 million people in the U.S. live with cancer and up to 25% of them have major depression. Depression leads to lower t...
ASSOCIATIONS BETWEEN ESCITALOPRAM AND PSILOCYBIN THERAPY AND BRAIN RESTING-STATE FUNCTIONAL CONNECTIVITY IN MAJOR DEPRESSIVE DISORDER
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
Psilocybin, a hallucinogen, distinctly impacts brain functional connectivity compared to Escitalopram in Major Depressive Disorder. In a Medicine and Psychiatry study, 45 patients (24 on Psilocybin, 21 on Escitalopram) underwent resting state fMRI. Both treatments reduced anhedonia and impulsivity. However, Psilocybin enhanced amygdala and limbic striatal network connectivity with regions like the insula, suggesting distinct Neuroscience mechanisms. Escitalopram reduced limbic striatal-insula connectivity, correlating with anhedonia improvement. This Clinical psychology research on Psychedelics and Drug Studies offers insights into Neurotransmitter Receptor Influence on Behavior for Mental Health Research Topics.
Abstract
Abstract Major Depressive Disorder (MDD) is a highly prevalent mental health condition characterized by symptoms including anhedonia, which is defi...